Danaher Corporation Announces Quarterly Dividend of $0.40 (NYSE:DHR)

Danaher Corporation (NYSE:DHR) declared a quarterly dividend on Tuesday, September 15th. Investors of record on Wednesday, September 30th will be paid a dividend of 0.40 per share by the conglomerate on Friday, October 30th. This represents a c) dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Wednesday, September 30th.

Danaher has increased its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 2 consecutive years. Danaher has a dividend payout ratio of 18.7% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Danaher to earn $9.26 per share next year, which means the company should continue to be able to cover its $1.60 annual dividend with an expected future payout ratio of 17.3%.

Danaher Trading Up 2.9%

DHR stock opened at $209.23 on Wednesday. Danaher has a 12-month low of $160.93 and a 12-month high of $242.80. The business’s 50-day moving average is $203.15 and its 200 day moving average is $191.90. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market cap of $147.09 billion, a price-to-earnings ratio of 37.16, a PEG ratio of 2.53 and a beta of 0.78.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.77 earnings per share. On average, sell-side analysts anticipate that Danaher will post 8.53 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on DHR. Wolfe Research downgraded Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Stifel Nicolaus lowered their target price on shares of Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. HSBC dropped their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Finally, Weiss Ratings upgraded shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.